SG11201700672YA - Immunological reagents binding to pd-1 - Google Patents
Immunological reagents binding to pd-1Info
- Publication number
- SG11201700672YA SG11201700672YA SG11201700672YA SG11201700672YA SG11201700672YA SG 11201700672Y A SG11201700672Y A SG 11201700672YA SG 11201700672Y A SG11201700672Y A SG 11201700672YA SG 11201700672Y A SG11201700672Y A SG 11201700672YA SG 11201700672Y A SG11201700672Y A SG 11201700672YA
- Authority
- SG
- Singapore
- Prior art keywords
- immunological reagents
- reagents binding
- binding
- immunological
- reagents
- Prior art date
Links
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 230000001900 immune effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033177P | 2014-08-05 | 2014-08-05 | |
| US201462053366P | 2014-09-22 | 2014-09-22 | |
| US201462093368P | 2014-12-17 | 2014-12-17 | |
| PCT/IB2015/055943 WO2016020856A2 (en) | 2014-08-05 | 2015-08-05 | Immunological reagents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201700672YA true SG11201700672YA (en) | 2017-02-27 |
Family
ID=53836144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700672YA SG11201700672YA (en) | 2014-08-05 | 2015-08-05 | Immunological reagents binding to pd-1 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9982053B2 (enExample) |
| EP (1) | EP3177644B1 (enExample) |
| JP (1) | JP6629321B2 (enExample) |
| KR (1) | KR102357893B1 (enExample) |
| CN (1) | CN107074947B (enExample) |
| AU (1) | AU2015298356B2 (enExample) |
| CA (1) | CA2957258C (enExample) |
| DK (1) | DK3177644T3 (enExample) |
| ES (1) | ES2847311T3 (enExample) |
| PL (1) | PL3177644T3 (enExample) |
| PT (1) | PT3177644T (enExample) |
| SG (1) | SG11201700672YA (enExample) |
| WO (1) | WO2016020856A2 (enExample) |
Families Citing this family (136)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250091300A (ko) | 2008-12-09 | 2025-06-20 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| US9982052B2 (en) * | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| DK3177644T3 (da) * | 2014-08-05 | 2021-01-11 | MabQuest SA | Immunologiske reagenser, som binder til PD-1 |
| HUE055115T2 (hu) | 2014-11-26 | 2021-10-28 | Xencor Inc | CD3-at és CD20-at kötõ heterodimer antitestek |
| MA44594B1 (fr) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| IL287916B2 (en) | 2015-07-30 | 2023-09-01 | Macrogenics Inc | Molecules that bind pd-1 and methods of using them |
| BR112018006237A2 (pt) | 2015-09-29 | 2018-10-09 | Celgene Corp | proteínas de ligação a pd-1 e métodos de uso das mesmas |
| HRP20220436T1 (hr) | 2015-11-03 | 2022-05-27 | Janssen Biotech, Inc. | Protutijela koja se specifično vežu na pd-1 i njihove uporabe |
| SG11201804839WA (en) | 2015-12-14 | 2018-07-30 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
| DK3964529T3 (da) | 2016-01-22 | 2025-06-30 | MabQuest SA | Ikke-blokerende pd1-specifikke antistoffer |
| US11214617B2 (en) * | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
| CN106008714B (zh) * | 2016-05-24 | 2019-03-15 | 瑞阳(苏州)生物科技有限公司 | 抗人pd-1人源化单克隆抗体及其应用 |
| KR102366813B1 (ko) | 2016-05-27 | 2022-02-24 | 아게누스 인코포레이티드 | 항-tim-3 항체 및 이의 사용 방법 |
| EP4257613A3 (en) * | 2016-06-14 | 2023-12-13 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| JP2019534859A (ja) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Ｐｄ−１結合タンパク質を使用して白斑を治療する方法 |
| US10751414B2 (en) | 2016-09-19 | 2020-08-25 | Celgene Corporation | Methods of treating psoriasis using PD-1 binding antibodies |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| CA3041684C (en) | 2016-11-01 | 2023-09-26 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| US10654929B2 (en) * | 2016-11-02 | 2020-05-19 | Jounce Therapeutics, Inc. | Antibodies to PD-1 and uses thereof |
| IL307242A (en) | 2016-12-07 | 2023-11-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| BR112019011582A2 (pt) | 2016-12-07 | 2019-10-22 | Agenus Inc. | anticorpos e métodos de utilização dos mesmos |
| WO2018127710A1 (en) * | 2017-01-06 | 2018-07-12 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| DK3565844T5 (da) | 2017-01-09 | 2024-09-02 | Tesaro Inc | Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer |
| MA47265A (fr) | 2017-01-13 | 2019-11-20 | Agenus Inc | Récepteurs de lymphocytes t qui se lient à ny-eso-1 et méthodes d'utilisation de ces derniers |
| CN107474135B (zh) * | 2017-02-17 | 2020-08-18 | 广西医科大学 | 抗PD-1的纳米抗体PD-1/Nb20及其制备方法与应用 |
| US11161905B2 (en) | 2017-03-04 | 2021-11-02 | Xiangtan Tenghua Bioscience | Recombinant antibodies to programmed death 1 (PD-1) and uses thereof |
| CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| WO2018191502A2 (en) | 2017-04-13 | 2018-10-18 | Agenus Inc. | Anti-cd137 antibodies and methods of use thereof |
| CN106939049B (zh) * | 2017-04-20 | 2019-10-01 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用 |
| RS64576B1 (sr) | 2017-05-01 | 2023-10-31 | Agenus Inc | Anti-tigit antitela i postupci njihove primene |
| CA3064435A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CR20190550A (es) * | 2017-06-05 | 2020-04-05 | Janssen Biotech Inc | Anticuerpos que se unen específicamente a pd-1 y métodos de uso |
| SG11202001319QA (en) | 2017-09-04 | 2020-03-30 | Agenus Inc | T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof |
| CN118909118A (zh) | 2017-09-07 | 2024-11-08 | 奥古斯塔大学研究所公司 | 程序性细胞死亡蛋白1抗体 |
| KR20200085828A (ko) | 2017-11-08 | 2020-07-15 | 젠코어 인코포레이티드 | 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체 |
| CN111699197B (zh) | 2017-11-13 | 2024-08-23 | 克雷森多生物制剂有限公司 | 结合cd137的单结构域抗体 |
| CN108218988B (zh) * | 2017-11-29 | 2019-10-11 | 广西医科大学 | 抗PD-1的纳米抗体PD-1/Nb52及其制备方法与应用 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| AR114127A1 (es) * | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
| CN119899267A (zh) * | 2018-03-22 | 2025-04-29 | 赛因格先进生物技术弗朗哥塞尔瓦托有限责任公司 | 拮抗性pd-1、pd-l1和lag-3结合蛋白 |
| CN112218883A (zh) | 2018-04-26 | 2021-01-12 | 艾吉纳斯公司 | 热休克蛋白结合肽组合物及其使用方法 |
| CN108840932B (zh) * | 2018-04-28 | 2022-03-29 | 中国科学院微生物研究所 | 一种pd-1特异性抗体及其抗肿瘤应用 |
| CN110404066B (zh) * | 2018-04-28 | 2022-06-17 | 齐鲁制药有限公司 | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 |
| SG11202012671QA (en) | 2018-06-20 | 2021-01-28 | Incyte Corp | Anti-pd-1 antibodies and uses thereof |
| KR20220008253A (ko) | 2019-01-03 | 2022-01-20 | 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) | 암을 앓는 대상에서 cd8+ t 세포 의존성 면역 반응을 향상시키기 위한 방법 및 약학적 조성물 |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| AU2020322021A1 (en) | 2019-07-30 | 2022-02-10 | Pairwise Plants Services, Inc. | Morphogenic regulators and methods of using the same |
| US11629190B2 (en) | 2019-08-15 | 2023-04-18 | Oregon State University | Canine antibody therapeutic for treating cancer |
| KR102231974B1 (ko) * | 2019-08-23 | 2021-03-25 | 한국과학기술원 | 사람의 프로그램된 세포사멸 단백질(pd-1)에 선택적으로 결합하는 신규한 폴리펩티드 및 이의 용도 |
| WO2021042019A1 (en) | 2019-08-30 | 2021-03-04 | Agenus Inc. | Anti-cd96 antibodies and methods of use thereof |
| WO2021081367A1 (en) | 2019-10-23 | 2021-04-29 | Pairwise Plants Services, Inc. | Compositions and methods for rna-templated editing in plants |
| WO2021087182A1 (en) | 2019-10-30 | 2021-05-06 | Pairwise Plants Services, Inc. | Type v crispr-cas base editors and methods of use thereof |
| US11926834B2 (en) | 2019-11-05 | 2024-03-12 | Pairwise Plants Services, Inc. | Compositions and methods for RNA-encoded DNA-replacement of alleles |
| JP2023502712A (ja) | 2019-11-21 | 2023-01-25 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法 |
| US11976278B2 (en) | 2019-12-06 | 2024-05-07 | Pairwise Plants Services, Inc. | Recruitment methods and compounds, compositions and systems for recruitment |
| US20210238598A1 (en) | 2020-01-30 | 2021-08-05 | Pairwise Plants Services, Inc. | Compositions, systems, and methods for base diversification |
| UY39058A (es) | 2020-01-31 | 2021-08-31 | Pairwise Plants Services Inc | Suppresión de la respuesta de evasión a la sombra en plantas |
| WO2021158798A1 (en) | 2020-02-04 | 2021-08-12 | Pairwise Plants Services, Inc. | Thornless / prickleless rubus plants |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| MX2022010215A (es) | 2020-02-21 | 2022-10-07 | Pairwise Plants Services Inc | Mejora de la resistencia al nematodo del quiste de la soja mediante edicion genetica. |
| US11999946B2 (en) | 2020-03-26 | 2024-06-04 | Pairwise Plants Services, Inc. | Methods for controlling meristem size for crop improvement |
| US11882808B2 (en) | 2020-03-27 | 2024-01-30 | Pairwise Plants Services, Inc. | Methods for improving resistance to soybean rust |
| WO2021207148A1 (en) | 2020-04-06 | 2021-10-14 | Pairwise Plants Services, Inc. | Methods and compositions for increasing resistance to ear rot and stem rot disease in maize |
| CN119431532A (zh) | 2020-04-16 | 2025-02-14 | 成对植物服务股份有限公司 | 控制分生组织大小以改良作物的方法 |
| MX2022013840A (es) * | 2020-05-04 | 2023-02-09 | Inhibrx Inc | Polipéptidos de unión a pd-1 canina y usos de los mismos. |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| CR20220596A (es) | 2020-05-26 | 2023-01-23 | Boehringer Ingelheim Int | Anticuerpos anti-pd-1 |
| CA3185017A1 (en) | 2020-06-02 | 2021-12-09 | Pairwise Plants Services, Inc. | Methods for controlling meristem size for crop improvement |
| UY39278A (es) | 2020-06-17 | 2022-01-31 | Pairwise Plants Services Inc | Métodos para el control del tamaño del meristemo para la mejora de cultivos |
| CA3187135A1 (en) | 2020-06-30 | 2022-01-06 | Pairwise Plants Services, Inc. | Compositions, systems, and methods for base diversification |
| JP2023539668A (ja) | 2020-08-28 | 2023-09-15 | ペアワイズ・プランツ・サーヴィシズ，インコーポレイテッド | 操作されたＣＲＩＳＰＲ－Ｃａｓタンパク質およびその使用方法 |
| AU2021374974A1 (en) | 2020-11-06 | 2023-05-25 | Pairwise Plants Services, Inc. | Compositions and methods for rna-encoded dna-replacement of alleles |
| CN117441015A (zh) | 2021-02-11 | 2024-01-23 | 成对植物服务股份有限公司 | 用于修饰植物中细胞分裂素氧化酶水平的方法和组合物 |
| US12365910B2 (en) | 2021-02-25 | 2025-07-22 | Pairwise Plants Services, Inc. | Methods and compositions for modifying root architecture in plants |
| CN113189078B (zh) * | 2021-03-04 | 2024-04-16 | 吉林大学 | 一种靶向药物的高通量筛选方法 |
| MX2023010499A (es) | 2021-03-09 | 2023-09-18 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cldn6. |
| US20220403475A1 (en) | 2021-06-14 | 2022-12-22 | Pairwise Plants Services, Inc. | Reporter constructs, compositions comprising the same, and methods of use thereof |
| AR126172A1 (es) | 2021-06-17 | 2023-09-27 | Pairwise Plants Services Inc | Modificación de factores de transcripción de la familia de factores reguladores del crecimiento en soja |
| UY39827A (es) | 2021-06-24 | 2023-01-31 | Pairwise Plants Services Inc | Modificación de genes de ubiquitina ligasa e3 hect para mejorar los rasgos de rendimiento |
| MX2023014883A (es) | 2021-07-01 | 2024-02-12 | Pairwise Plants Services Inc | Metodos y composiciones para mejorar el desarrollo del sistema radicular. |
| CN113702351B (zh) * | 2021-07-14 | 2024-08-20 | 吉林大学 | 一种对天然药物产物进行筛选和垂钓的方法 |
| CA3229056A1 (en) | 2021-08-12 | 2023-02-16 | Pairwise Plants Services, Inc. | Modification of brassinosteroid receptor genes to improve yield traits |
| UY39902A (es) | 2021-08-17 | 2023-03-31 | Pairwise Plants Services Inc | Métodos y composiciones para modificar genes de histidina quinasa receptores de citoquinina en plant |
| MX2024002276A (es) | 2021-08-30 | 2024-03-07 | Pairwise Plants Services Inc | Modificacion de genes de peptidasa de union a ubiquitinaen plantas para mejorar rasgos de rendimiento. |
| AR126938A1 (es) | 2021-09-02 | 2023-11-29 | Pairwise Plants Services Inc | Métodos y composiciones para mejorar la arquitectura de las plantas y los rasgos de rendimiento |
| US20230266293A1 (en) | 2021-09-21 | 2023-08-24 | Pairwise Plants Services, Inc. | Color-based and/or visual methods for identifying the presence of a transgene and compositions and constructs relating to the same |
| EP4405377A1 (en) | 2021-09-21 | 2024-07-31 | Pairwise Plants Services, Inc. | Methods and compositions for reducing pod shatter in canola |
| UY39966A (es) | 2021-10-04 | 2023-04-28 | Pairwise Plants Services Inc | Métodos para mejorar la fertilidad de la flor y el rendimiento de semillas |
| CA3234455A1 (en) | 2021-10-07 | 2023-04-13 | Pairwise Plants Services, Inc. | Methods for improving floret fertility and seed yield |
| UY40060A (es) | 2021-12-09 | 2023-07-14 | Pairwise Plants Services Inc | Métodos para mejorar la fertilidad de floretes y el rendimiento de semillas |
| US20230295646A1 (en) | 2021-12-13 | 2023-09-21 | Pairwise Plants Services, Inc. | Model editing systems and methods relating to the same |
| US20250146008A1 (en) | 2022-01-06 | 2025-05-08 | Pairwise Plants Services, Inc. | Methods and compositions for trichome removal |
| CA3243281A1 (en) | 2022-01-28 | 2023-08-03 | Georgiamune Inc | ANTIBODIES DIRECTED AGAINST PROGRAMMED CELL DEATH PROTEIN 1 PD-1 AGONISTS |
| AR128372A1 (es) | 2022-01-31 | 2024-04-24 | Pairwise Plants Services Inc | Supresión de la respuesta de evitación de la sombra en las plantas |
| WO2023164722A1 (en) | 2022-02-28 | 2023-08-31 | Pairwise Plants Services, Inc. | Engineered crispr-cas effector proteins and methods of use thereof |
| WO2023168217A1 (en) | 2022-03-02 | 2023-09-07 | Pairwise Plants Services, Inc. | Modification of brassinosteroid receptor genes to improve yield traits |
| CN115015536A (zh) * | 2022-03-30 | 2022-09-06 | 邹灵龙 | 一种即时检测pd-1抗体药浓度的试纸条和试剂盒 |
| WO2023192838A1 (en) | 2022-03-31 | 2023-10-05 | Pairwise Plants Services, Inc. | Early flowering rosaceae plants with improved characteristics |
| AU2023251095A1 (en) | 2022-04-07 | 2024-10-17 | Monsanto Technology Llc | Methods and compositions for improving resistance to fusarium head blight |
| CN119278208A (zh) | 2022-04-21 | 2025-01-07 | 成对植物服务股份有限公司 | 用于改善产量性状的方法和组合物 |
| US20230348922A1 (en) | 2022-05-02 | 2023-11-02 | Pairwise Plants Services, Inc. | Methods and compositions for enhancing yield and disease resistance |
| CA3250542A1 (en) | 2022-05-05 | 2023-11-09 | Pairwise Plants Services Inc | METHODS AND COMPOSITIONS FOR MODIFYING ROOT ARCHITECTURE OR IMPROVING PLANT YIELD PROPERTIES |
| UY40326A (es) | 2022-06-27 | 2023-12-29 | Pairwise Plants Services Inc | Métodos y composiciones para modificar el escape a la sombra en plantas |
| AR129749A1 (es) | 2022-06-29 | 2024-09-25 | Pairwise Plants Services Inc | Métodos y composiciones para controlar el tamaño del meristemo para el mejoramiento de cultivos |
| US20240002873A1 (en) | 2022-06-29 | 2024-01-04 | Pairwise Plants Services, Inc. | Methods and compositions for controlling meristem size for crop improvement |
| WO2024030984A1 (en) | 2022-08-04 | 2024-02-08 | Pairwise Plants Services, Inc. | Methods and compositions for improving yield traits |
| WO2024036240A1 (en) | 2022-08-11 | 2024-02-15 | Pairwise Plants Services, Inc. | Methods and compositions for controlling meristem size for crop improvement |
| WO2024054880A1 (en) | 2022-09-08 | 2024-03-14 | Pairwise Plants Services, Inc. | Methods and compositions for improving yield characteristics in plants |
| AU2023395894A1 (en) | 2022-12-16 | 2025-06-05 | Pairwise Plants Services, Inc. | Fusion proteins comprising an intein polypeptide and methods of use thereof |
| CN120359295A (zh) | 2022-12-21 | 2025-07-22 | 成对植物服务股份有限公司 | 工程化蛋白质和其使用方法 |
| CN120603841A (zh) | 2023-02-16 | 2025-09-05 | 成对植物服务股份有限公司 | 用于改变植物避荫性的方法和组合物 |
| WO2024182746A1 (en) | 2023-03-01 | 2024-09-06 | Pairwise Plants Services, Inc. | Engineered proteins and methods of use thereof |
| AR132019A1 (es) | 2023-03-02 | 2025-05-21 | Pairwise Plants Services Inc | Métodos y composiciones para modificar la evitación de la sombra en plantas |
| AR132071A1 (es) | 2023-03-09 | 2025-05-21 | Pairwise Plants Services Inc | Modificación de genes de la vía de señalización de brasinoesteroide para mejorar rasgos de rendimiento en plantas |
| AU2024248777A1 (en) | 2023-03-30 | 2025-10-02 | Pairwise Plants Services, Inc. | Methods and compositions for reducing thorns or prickles in plants |
| WO2024216028A1 (en) | 2023-04-12 | 2024-10-17 | Agenus Inc. | Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor |
| AU2024269008A1 (en) | 2023-05-10 | 2025-11-27 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
| UY40746A (es) | 2023-05-18 | 2024-12-13 | Pairwise Plants Services Inc | Métodos y composiciones para mejorar las características de rendimiento de las plantas |
| AR133164A1 (es) | 2023-07-18 | 2025-09-03 | Pairwise Plants Services Inc | Métodos y composiciones para modificar la arquitectura radicular en plantas |
| AR133310A1 (es) | 2023-07-27 | 2025-09-17 | Pairwise Plants Services Inc | Métodos y composiciones para modificar rasgos de rendimiento de las plantas |
| WO2025064734A1 (en) | 2023-09-21 | 2025-03-27 | Pairwise Plants Services, Inc. | Early flowering black raspberry plants with improved characteristics |
| WO2025072453A1 (en) | 2023-09-26 | 2025-04-03 | Pairwise Plants Services, Inc. | Engineered deaminases, compositions comprising the same, and methods of use thereof |
| WO2025080537A1 (en) | 2023-10-09 | 2025-04-17 | Pairwise Plants Services, Inc. | Circular permutants of cas12a |
| US20250122522A1 (en) | 2023-10-11 | 2025-04-17 | Pairwise Plants Services, Inc. | Methods and compositions for improving crop yield traits |
| US20250207154A1 (en) | 2023-12-21 | 2025-06-26 | Pairwise Plants Services, Inc. | Compositions and methods for rna-encoded dna-replacement of alleles |
| WO2025178902A1 (en) | 2024-02-22 | 2025-08-28 | Pairwise Plants Services, Inc. | Methods and compositions for improving yield characteristics in plants |
| US12428636B1 (en) | 2024-07-08 | 2025-09-30 | Pairwise Plants Services, Inc. | Methods and compositions for modification of protospacer adjacent motif specificity of CAS12A |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
| EP0347425B1 (en) | 1987-03-02 | 1995-12-27 | Whitehead Institute For Biomedical Research | Recombinant mycobacterial vaccine |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990014363A1 (en) | 1989-05-19 | 1990-11-29 | Amgen Inc. | Metalloproteinase inhibitor |
| CA2076753A1 (en) | 1990-02-26 | 1991-08-27 | Anthony J. Radford | Shuttle plasmid for escherichia coli and mycobacteria |
| GB9015888D0 (en) | 1990-07-19 | 1990-09-05 | Smithkline Biolog | Vectors |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0587775A4 (en) | 1991-06-06 | 1994-11-02 | Medimmune Inc | INDUCTION OF THE CTL RESPONSE BY FOREIGN ANTIGENS EXPRESSED IN MYCOBACTERIES. |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| JP3454275B2 (ja) | 1992-06-05 | 2003-10-06 | 佑 本庶 | プログラムされた細胞死に関連した新規なポリペプチドおよびそれをコードするｄｎａ |
| AU7203194A (en) | 1993-06-04 | 1995-01-03 | New York University | Bispecific human monoclonal antibodies specific for human immunodeficiency virus |
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| MXPA02001877A (es) | 1999-08-23 | 2002-08-20 | Dana Farber Cancer Inst Inc | Pd-1, un receptor para b7-4, y usos del mismo. |
| ATE524495T1 (de) | 2001-07-31 | 2011-09-15 | Ono Pharmaceutical Co | Pd-1-spezifische substanz |
| WO2004004771A1 (ja) | 2002-07-03 | 2004-01-15 | Ono Pharmaceutical Co., Ltd. | 免疫賦活組成物 |
| MXPA05006828A (es) * | 2002-12-23 | 2005-09-08 | Wyeth Corp | Anticuerpos contra pd-1, y sus usos. |
| EP1587907B1 (en) | 2003-01-07 | 2011-03-02 | Dyax Corporation | Kunitz domain library |
| EP2270051B1 (en) | 2003-01-23 | 2019-05-15 | Ono Pharmaceutical Co., Ltd. | Antibody specific for human PD-1 and CD3 |
| JP4361545B2 (ja) * | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 |
| KR101804078B1 (ko) | 2005-06-08 | 2017-12-01 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
| BRPI0720724A2 (pt) | 2006-12-27 | 2014-04-01 | Univ Emory | Composições e métodos para o tratamento de infecções e tumores |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| WO2009114335A2 (en) * | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| TW201007669A (en) | 2008-08-01 | 2010-02-16 | Integrated Solutions Technology Inc | A display driving device and the driving method thereof |
| EP2342228B1 (en) * | 2008-09-12 | 2017-09-06 | Oxford University Innovation Limited | Pd-1 specific antibodies and uses thereof |
| EP2342229A1 (en) | 2008-09-12 | 2011-07-13 | ISIS Innovation Limited | Pd-1 specific antibodies and uses thereof |
| AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| CA2791930A1 (en) * | 2010-03-11 | 2011-09-15 | Kerry Louise Tyson | Pd-1 antibody |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| EP2638061B1 (en) | 2010-11-11 | 2015-04-22 | The University of Hong Kong | Soluble pd-1 variants, fusion constructs, and uses thereof |
| PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| MX338353B (es) | 2011-04-20 | 2016-04-13 | Medimmune Llc | Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1. |
| US9090994B2 (en) | 2011-06-08 | 2015-07-28 | Nanjingjinsirui Science & Technology Biology Corp. | Antibody humanization by framework assembly |
| AR087405A1 (es) | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| WO2013126809A1 (en) * | 2012-02-23 | 2013-08-29 | Sloan-Kettering Institute For Cancer Research | Prediction of responsiveness to treatment with immunomodulatory therapeutics and method of monitoring abscopal effects during such treatment |
| WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| EP2904011B1 (en) | 2012-10-02 | 2017-08-23 | Bristol-Myers Squibb Company | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| HRP20221262T1 (hr) * | 2013-09-13 | 2022-12-09 | Beigene Switzerland Gmbh | Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| US9982052B2 (en) * | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| DK3177644T3 (da) * | 2014-08-05 | 2021-01-11 | MabQuest SA | Immunologiske reagenser, som binder til PD-1 |
| US10239942B2 (en) | 2014-12-22 | 2019-03-26 | Pd-1 Acquisition Group, Llc | Anti-PD-1 antibodies |
| US11214617B2 (en) * | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
| DK3964529T3 (da) * | 2016-01-22 | 2025-06-30 | MabQuest SA | Ikke-blokerende pd1-specifikke antistoffer |
-
2015
- 2015-08-05 DK DK15750136.2T patent/DK3177644T3/da active
- 2015-08-05 EP EP15750136.2A patent/EP3177644B1/en active Active
- 2015-08-05 US US15/329,760 patent/US9982053B2/en active Active
- 2015-08-05 SG SG11201700672YA patent/SG11201700672YA/en unknown
- 2015-08-05 AU AU2015298356A patent/AU2015298356B2/en active Active
- 2015-08-05 WO PCT/IB2015/055943 patent/WO2016020856A2/en not_active Ceased
- 2015-08-05 CN CN201580042199.7A patent/CN107074947B/zh active Active
- 2015-08-05 JP JP2017526774A patent/JP6629321B2/ja active Active
- 2015-08-05 ES ES15750136T patent/ES2847311T3/es active Active
- 2015-08-05 CA CA2957258A patent/CA2957258C/en active Active
- 2015-08-05 PT PT157501362T patent/PT3177644T/pt unknown
- 2015-08-05 KR KR1020177004575A patent/KR102357893B1/ko active Active
- 2015-08-05 PL PL15750136T patent/PL3177644T3/pl unknown
-
2018
- 2018-05-17 US US15/981,977 patent/US11130807B2/en active Active
-
2021
- 2021-09-27 US US17/485,752 patent/US20220169733A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016020856A3 (en) | 2016-03-31 |
| JP6629321B2 (ja) | 2020-01-15 |
| EP3177644A2 (en) | 2017-06-14 |
| ES2847311T3 (es) | 2021-08-02 |
| US9982053B2 (en) | 2018-05-29 |
| US20220169733A1 (en) | 2022-06-02 |
| WO2016020856A2 (en) | 2016-02-11 |
| PT3177644T (pt) | 2021-01-13 |
| US20170226210A1 (en) | 2017-08-10 |
| DK3177644T3 (da) | 2021-01-11 |
| KR102357893B1 (ko) | 2022-02-04 |
| PL3177644T3 (pl) | 2021-06-14 |
| US20190106493A1 (en) | 2019-04-11 |
| AU2015298356A1 (en) | 2017-02-16 |
| CN107074947A (zh) | 2017-08-18 |
| CA2957258C (en) | 2023-11-07 |
| KR20170069996A (ko) | 2017-06-21 |
| CN107074947B (zh) | 2021-04-09 |
| JP2017531028A (ja) | 2017-10-19 |
| AU2015298356B2 (en) | 2020-11-19 |
| CA2957258A1 (en) | 2016-02-11 |
| EP3177644B1 (en) | 2020-10-07 |
| US11130807B2 (en) | 2021-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285287B1 (en) | Antibodies to tigit | |
| SG11201700672YA (en) | Immunological reagents binding to pd-1 | |
| IL267798B (en) | Human antibodies to pd-1 | |
| IL261188A (en) | Antibodies against tigit | |
| IL256844A (en) | pd-1 antibodies | |
| IL256499A (en) | Antibodies to CD40 | |
| IL249187A0 (en) | Antibodies to il-15 | |
| PL3146010T3 (pl) | Środki wiążące | |
| ZA201604640B (en) | Novel anti-netrin-1 antibody | |
| PL3628731T3 (pl) | Nowe przeciwciało przeciwko presepsynie | |
| ZA201800781B (en) | Pd-1 antibodies | |
| HK1244290A1 (en) | Antibodies to tigit | |
| GB201507228D0 (en) | Antibodies to IL-24 | |
| AU2014903840A0 (en) | Immunological reagent | |
| AU2014903652A0 (en) | Immunological reagent | |
| GB201409276D0 (en) | Improvements to vehicle transmissions | |
| AU2014902976A0 (en) | App to app payment | |
| GB201417640D0 (en) | Binding Assay Analysis |